Prairiewood Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History

Prairiewood Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$25.33 - $34.25 $1.1 Million - $1.48 Million	-43,345 Closed	0 $0
Q1 2022 Apr 20, 2022	SELL	$28.51 - $32.9 $30,505 - $35,203	-1,070 Reduced 2.41%	43,345 $1.4 Million
Q4 2021 Jan 20, 2022	SELL	$26.37 - $34.22 $23,258 - $30,182	-882 Reduced 1.95%	44,415 $1.3 Million
Q3 2021 Oct 13, 2021	SELL	$23.54 - $31.39 $16,148 - $21,533	-686 Reduced 1.49%	45,297 $1.21 Million
Q1 2021 Apr 13, 2021	BUY	$24.15 - $31.45 $43,663 - $56,861	1,808 Added 4.09%	45,983 $1.2 Million
Q4 2020 Jan 15, 2021	BUY	$17.7 - $25.81 $781,897 - $1.14 Million	44,175 New	44,175 $1.11 Million

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.93B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Prairiewood Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Prairiewood Capital, LLC with notifications on news.